Revision 1

#2879 Store at -20C

LITAF Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source:	UniProt ID:	Entrez-Gene Id:
WB	H	Endogenous	23	Rabbit	#Q99732	9516

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

LITAF Antibody dectects endogenous levels of total human LITAF protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human LITAF protein. Antibodies were purified by peptide affinity chromatography.

Background

LITAF (PIG7/SIMPLE) is protein that contributes to the regulation of the inflammatory cytokine TNF-α (1-3). LITAF was identified as a transcription factor involved in LPS-induced TNF-α expression through interaction with the TNF-α promoter (1,4). The same protein, called PIG7, was independently described in a model for p53 regulation (2). A putative alternative spiced form of LITAF, named SIMPLE, encodes a protein with a unique carboxyl terminus (3). Studies on LITAF-deficient mice demonstrate that LITAF plays a significant role in the regulation of several inflammatory cytokines in response to LPS (5). The regulation of LITAF can occur through phosphorylation by p38α via the TLR pathway that leads to its nuclear translocation (5). Mutation in the LITAF/SIMPLE gene has been associated with an autosomal dominant demyelinating form of Charcot-Marie-Tooth disease (6).

Background References

1. Myokai, F. et al. (1999) *Proc. Natl. Acad. Sci. USA* 96, 4518-4523.
2. Zhu, J. et al. (1999) *Oncogene* 18, 2149-2155.
3. Moriwaki, Y. et al. (2001) *J. Biol. Chem.* 276, 23065-23076.
4. Tang, X. et al. (2003) *Proc. Natl. Acad. Sci. USA* 100, 4096-4101.
5. Tang, X. et al. (2006) *Proc. Natl. Acad. Sci. USA* 103, 13777-13782.
6. Street, V.A. et al. (2003) *Neurology* 60, 22-26.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
X: Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
GP: Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Limited Uses

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.